Tag

Metformin

All articles tagged with #metformin

science1 day ago•5 min saved

Metformin May Boost Lifespan for Older Women, Study Suggests

A long-term, observational study of 438 postmenopausal women with type 2 diabetes found that those who started metformin had about a 30% lower risk of dying before age 90 compared with those starting a sulfonylurea. The researchers caution that the design cannot prove causation, with no placebo group and limited generalizability to men or younger people, but the roughly 14–15 years of follow-up adds evidence to metformin’s potential anti-aging effects and the geroscience hypothesis, warranting randomized trials.

via ScienceAlert|

#aging #diabetes #longevity

science5 days ago•7 min saved

Metformin’s Hidden Target: The Gut Takes Center Stage

New Northwestern University research in mice shows metformin mainly acts in the intestine, lowering blood sugar by reducing mitochondrial activity in gut cells and prompting them to burn more glucose, challenging the idea that the liver is the primary target. Published in Nature Metabolism, the study links berberine to a similar gut pathway and uses engineered mice to show that blocking mitochondrial complex I in the gut is central to metformin’s effect, with implications for gut-targeted diabetes therapies.

via SciTechDaily|

#diabetes #gut #intestine

science17 days ago•72 min saved

Gut-Targeted Complex I Blockade Reveals Metformin’s Glucose-Lowering Mechanism

A Nature Metabolism study shows metformin lowers glucose by acutely inhibiting mitochondrial complex I specifically in intestinal epithelium, reducing citrulline production and boosting GDF15, thereby reprogramming the gut into a glucose sink that takes up glucose and converts it to lactate; phenformin and berberine act via the same intestine-specific Complex I mechanism, and the effect depends on short-term bolus exposure rather than chronic dosing.

via Nature|

#citrulline #gdf15 #intestine

science17 days ago•9 min saved

Metformin targets gut mitochondria to boost glycemic control

New metabolomic and mouse studies show metformin lowers blood glucose by selectively inhibiting mitochondrial complex I in the intestinal epithelium, increasing intestinal glucose use and improving postprandial glycemic control, with raised levels of GDF15 and N-lactoyl-phenylalanine linked to systemic glucose regulation.

via Nature|

#glycemic-control #intestine #metformin

science1 month ago•9 min saved

Diabetes drug metformin hints at long-term HIV control after stopping therapy

New immunology research links specific immune-cell patterns and two genes (DDIT4 and ZNF254) to longer ART-free control of HIV; metformin can activate one of these mechanisms to keep HIV dormant, delaying or potentially preventing rebound after treatment interruption. Analyses of ART-interruption trials showed higher levels of stem cell–memory CD8+ T cells and certain natural killer cells associated with slower rebound. This supports a block-and-lock strategy using metformin or similar drugs, with preclinical and clinical testing planned by the HOPE Collaboratory to pursue HIV silencing while reducing inflammation.

via SciTechDaily|

#hiv #hiv-reservoir #immune-cells

health1 month ago•8 min saved

Metformin Reimagined: A 100-Year-Old Drug Tackles Hyperemesis Gravidarum

A health feature follows researchers and patients exploring metformin, a diabetes drug, as a potential preventive treatment for hyperemesis gravidarum (HG) by modulating the nausea-related hormone GDF15. Early observational data suggest taking metformin before conception may significantly reduce HG risk, with clinical trials in the works. The drug’s affordability, safety history, and broad off-label use—ranging from fertility in PCOS to obesity and potential antiaging effects—have spurred widespread interest, though more rigorous research is needed. The piece also shares the lived experience of HG and a patient hopeful that metformin could improve future pregnancies.

via Women's Health|

#gdf15 #health #hyperemesis-gravidarum

science1 month ago•7 min saved

New Brain Mechanism Reveals How Metformin Lowers Blood Sugar

Scientists discovered that metformin lowers blood sugar not only via the liver and gut but also by acting in the brain. In mice, metformin inhibits Rap1 in the ventromedial hypothalamus, activating SF1 neurons and reducing glucose; surprisingly small brain doses produced effects, and removing Rap1 from VMH abolished metformin’s action, illustrating a distinct brain pathway that could enable lower-dose, brain-targeted diabetes therapies in the future.

via SciTechDaily|

#brain #diabetes #hypothalamus

science1 month ago•6 min saved

Metformin Sparks Exercise-Mode Metabolism in Prostate Cancer Care

Researchers report metformin increases Lac-Phe, a molecule tied to energy use and appetite, in prostate cancer patients who aren’t exercising, mimicking an exercise signal and potentially supporting metabolic health during treatment; the effect is not linked to tumor control and requires further study.

via SciTechDaily|

#exercise-signal #lac-phe #metabolic-health

science2 months ago•6 min saved

Metformin’s brain pathway unlocked: Rap1 in the hypothalamus drives glucose control

Scientists reveal metformin lowers blood sugar by acting in the brain, specifically by suppressing Rap1 in the ventromedial hypothalamus and activating SF1 neurons, with brain effects at far lower drug levels than previously thought, opening possibilities for brain-targeted diabetes therapies and potential brain-health benefits.

via ScienceDaily|

#brain #glucose #hypothalamus

science2 months ago•6 min saved

Metformin's Brain Pathway Unveiled, Paving Way for Next-Gen Diabetes Treatments

New research shows metformin can act in the brain, reaching the ventromedial hypothalamus and inhibiting Rap1 signaling in SF1 neurons to help regulate glucose in mice, a mechanism distinct from its liver and gut effects. When Rap1 was removed, metformin no longer helped diabetes-like symptoms, suggesting a brain pathway. This could lead to brain-targeted diabetes therapies and broaden metformin’s uses, though human studies are needed and side effects like GI distress and kidney risk remain concerns; the drug is also linked to aging benefits.

via ScienceAlert|

#brain #metformin #rap1

health2 months ago•4 min saved

Old Diabetes Drug Metformin Shows Brain-Led Control of Metabolism

New preclinical work links metformin’s metabolic effects to the brain, showing it acts in the hypothalamus via the Rap1 pathway to enhance central insulin signaling and reduce liver glucose production in mice. This brain-first mechanism could reshape diabetes and obesity therapies, informing drug combinations and trial endpoints, but human validation is needed and questions remain about dosing, blood–brain barrier crossing, and interactions with AMPK.

via Iowa Park Leader|

#brain-metabolism #diabetes #health

health2 months ago•9 min saved

Budget-Friendly Metformin Cuts Insulin Dose in Type 1 Diabetes, Trial Shows

A 26-week randomized trial (INTIMET) in 40 adults with long-standing type 1 diabetes found metformin did not improve insulin resistance or glucose control, but reduced total daily insulin requirements by about 12% compared with placebo, suggesting metformin may ease the insulin burden rather than reverse insulin resistance; researchers are exploring whether gut microbiome interactions explain the effect.

via SciTechDaily|

#clinical-trial #health #insulin-reduction

science3 months ago•3 min saved

Metformin May Extend Longevity for Older Women, Study Finds

A study of 438 postmenopausal women with type 2 diabetes suggests that starting metformin is associated with about a 30% lower risk of dying before age 90 compared with sulfonylurea therapy, hinting at metformin's potential aging‑related benefits. However, the findings are observational (not randomized), with no placebo group and a modest sample size; the long follow‑up of 14–15 years strengthens the signal but cannot prove causality, and randomized trials are needed to confirm longevity effects.

via ScienceAlert|

#aging #diabetes #geroscience

health3 months ago•45 min saved

Diabetes Drug Metformin Linked to Slower Age-Related Vision Loss

A Liverpool study of about 2,000 adults with diabetes aged 50+ found that those taking metformin had 37% lower odds of developing intermediate age-related macular degeneration (AMD) over five years compared with non-users, suggesting metformin might help slow age-related vision loss. However, researchers caution that the findings are observational and do not prove causation or support using metformin to treat AMD outside of diabetes; clinical trials are needed to confirm any benefit.

via Healthline|

health3 months ago•7 min saved

Metformin May Cut Long-COVID Risk When Used During COVID, Review Finds

A literature review of randomized trials and health-record analyses suggests that taking metformin during acute COVID-19 can reduce the risk of developing long COVID by roughly 40%–60%, though it is studied for prevention rather than treatment of existing long COVID; findings, including the COVID-OUT trial and EHR-based studies, have replicated this protective effect and point to possible antiviral benefits and compatibility with other antivirals, making metformin a potential low-cost outpatient preventive option.

via CIDRAP|

#covid-19 #electronic-health-records #health